IFN-α has also been successfully used in the treatment of viral hepatitis, associated or not with HIV infection, and pegylated IFN-α is still an integral part of the treatment of choice for HBV and HCV (reviewed in [62,63]). This evidence concerns the gene IFNA2 and viral hepatitis.